FentaNYL Patch Fatalities Linked to ‘Bystander Apathy’

September/October 2013


FentaNYL Patch Fatalities Linked to ‘Bystander Apathy’


ISMP just learned about another child that died after gaining access to a transdermal fentaNYL patch. This time it was a 15-month-old boy who had been cuddling with his mother, sleeping on her chest as they both took a nap. The boy’s mother had been wearing a fentaNYL patch on her chest to treat pain associated with multiple sclerosis. When the mother awoke, she found her son unresponsive. The child was rushed by ambulance to the hospital. Resuscitation efforts continued in a pediatric emergency department without success. The child’s mother noticed that the patch on her chest was missing. The baby apparently ingested the patch, although the patch was never found. During intubation, vomitus was visualized in the baby’s esophagus and trachea, indicating aspiration, and perhaps the patch was overlooked in the vomitus. A medical examiner confirmed the child’s access to the patch, revealing physical findings of pulmonary congestion and edema, and toxicology findings of acute fentaNYL intoxication.

Repeated Tragic Events
Sadly, this is a recurring story in healthcare—one that has been told over and over again without substantial acknowledgement and action by individual practitioners, healthcare organizations and systems, community pharmacies, public policy agencies, pharmaceutical companies, professional organizations, and advocacy groups. The prior events are just as heartbreaking as the latest event. A 2-year-old boy died after ingesting a used fentaNYL patch that stuck to the wheels of his toy truck while playing in his grandmother’s room at a long-term care facility (National Alert Network, 2012). A 1-year-old girl swallowed a 25 mcg/hour fentaNYL patch that had been lying on the floor and was found dead just 2 hours after her parents tucked her into bed and kissed her goodnight (Teske et al., 2007). Other fatalities have occurred with confused elderly adults and opioid-abusing teens and adults who have chewed and/or ingested fentaNYL patches (Faust et al., 2011).

Absorption of Ingested FentaNYL Patches
Transdermal fentaNYL is designed to release the drug in a slow, steady manner over 72 hours. But uncontrolled quantities of the drug may be rapidly absorbed via the buccal route if the patch is ingested, often with disastrous results (Carson et al., 2010). The rate of drug absorption and severity of toxicity is dependent on the amount of time the fentaNYL patch is in direct contact with the oral mucosa and whether the patch is chewed/sucked on or swallowed intact. A patch chewed or sucked on will release large quantities of drug rapidly. Chewing is particularly dangerous because it disrupts the patch integrity and releases a full dose in a much shorter period of time than an intact patch (Faust et al., 2011). Also, fentaNYL is absorbed more rapidly through buccal mucosa (Carson et al., 2010) and has more than a 30-fold increase in absorption when compared to transdermal absorption (Mrvos et al., 2012). Swallowing an intact patch results in less rapid drug release, but systemic absorption is still significant (Teske et al., 2007; Faust et al., 2011; Carson et al., 2010; Mrvos et al., 2012).

Given that each patch holds a relatively large dose of fentaNYL, and that about half of the total drug amount remains in a patch after 3 days of use (Teske, 2007), chewing or sucking on a patch—even a used one—can result in a large overdose. Faust et al. (2011) provides the following example. A 50 mcg/hour patch the authors tested held nearly 8,400 mcg of fentaNYL (the actual amount varies depending on design of the patch). If the patch in this example and its entire contents were ingested intact, about 1,680 mcg would enter the systemic circulation. If the entire contents of the patch were removed (by chewing, for example) and absorbed buccally, the dose entering the circulation would be about three times higher (about 5,000 mcg) than swallowing the patch intact.

Other FentaNYL Patch Tragedies
Children have also been victims of fatal fentaNYL overdoses after they applied a patch intended for an adult to their skin. A 4-year-old child died after finding a used fentaNYL patch in a trashcan and placing it on his body like a Band-Aid (ISMP, 2012). An uninformed mother placed a fentaNYL patch, which had been prescribed for the mother after a car accident, on her 6-year-old daughter’s neck when the young child complained of neck pain before going to bed; the child was found dead the next morning. The US Food and Drug Administration (FDA) evaluated 26 cases of pediatric accidental exposures to fentaNYL patches reported during the past 15 years (US FDA, 2012). Of these, 10 resulted in death and 12 in hospitalization. Sixteen of the 26 cases occurred in children 2 years old or younger. The mobility and curiosity of young children provide ample opportunity to find fallen patches, improperly discarded patches, or improperly stored patches.

Opioid-naïve adults have also fared poorly when prescribed fentaNYL patches inappropriately for acute pain or when instructions for use were not provided and understood. For example, an otherwise healthy opioid-naïve 47-year-old man died 1 day after discharge from a hospital where he was given a prescription for fentaNYL patches for post-operative pain following spinal surgery (Neary, 2013). A 77-year-old woman was found dead at home with multiple fentaNYL patches on her body and a heating pad over one of the patches (ISMP, 2005).

Impetus for Change
Can you imagine the grief of the parents who found their lifeless children, or the family members who lost their loved ones to this preventable event? Healthcare professionals typically exhibit profound empathy for those who suffer such a loss, but not all may feel personally responsible to prevent these events. What if you were the physician who prescribed a fentaNYL patch that led to a fatal event, or a community pharmacist who dispensed the patch involved in a fatal outcome, or the nurse who discharged a patient from the hospital with a prescription for a fentaNYL patch that ultimately resulted in such a tragedy? Must it take personal involvement in an actual event for all individuals to feel the weight of these fatal errors and incite preventive action?

Bystander Apathy
Until each and every healthcare professional, health system, community pharmacy, pharmaceutical company, public policy agency, and professional organization potentially associated with fentaNYL patches and the patients who use them accept personal responsibility for promoting safe use of this powerful opioid, we are exposing one of the most troubling examples of bystander apathy in healthcare.

Bystander apathy is not caused by an indifference to patient laziness, apathy, or lack of concern for patients but rather by a belief that others in a group who see the same risks will intervene (Geller, 2001). Studies have shown that people are less likely to intervene when other people are also able to help (Geller, 2001). When groups of people are involved, the responsibility to act is diffuse rather than personal. We can easily convince ourselves that our personal action is not needed. Perhaps someone else more qualified will take care of the problem or address the issue. The sad truth is, we are all complicit if we continue to allow these tragic, preventable events to happen.

Preventing FentaNYL Patch Tragedies
The prescribing physician and the discharging nurse cannot just rely on each other or a hospital/community pharmacist to verify the appropriateness of fentaNYL patches and doses, or to educate patients about important risks and proper use. The hospital/community pharmacist cannot simply assume the drug and dose is appropriate or that the patient has been educated. All healthcare providers must individually instruct patients and caregivers about proper use and risks. Professional associations that support physicians, pharmacists, and nurses cannot remain silent on this important issue. Safety organizations, including ISMP, need to step up efforts to make fentaNYL patch safety among the highest priorities. Pharmaceutical companies can no longer sidestep improved label warnings, fail to provide secure disposal containers for patches, or ignore further exploration of steps to prevent misuse and errors, such as making the patch wholly unpalatable. Professional licensing agencies and accrediting organizations need to set standards regarding patient education that specifically address the risks associated with fentaNYL patches. The FDA needs to expand its Risk Evaluation and Mitigation Strategies (REMS) for long-acting opioids to include required patient education by prescribers, pharmacists, and nurses, and the agency needs proper legislative authority to require prescriber education or perhaps a special restricted distribution program for the drug. This time around, we hope organized groups that represent pharmacy chains, pharmacy boards, and pharmacy practice will support expansion of the REMS to include pharmacists in consumer education for long-acting opioids, including fentaNYL patches.

Focused Education
Patients who are using a fentaNYL patch, or their caregivers, need to know about proper use, storage, and disposal, and other risks, particularly when using the patches around children. To assist, ISMP has developed a FREE patient education checklist and consumer leaflet for use during consumer education that can then be given to the patient for reference (download the checklist/leaflet at: www.ismp.org/AHRQ/default.asp [must register for initial access]). The checklist/ leaflet includes, among other important information, 10 key safety tips for consumers using fentaNYL patches (safety tips listed in Table 1 in the PDF version of the newsletter). FDA also requires a Medication Guide (www.ismp.org/sc?id=219) to be given to patients, and the agency has developed a Safe Use Initiative (www.ismp.org/sc?id=220) around proper disposal of the patches It’s one thing to tell people to read these materials and hope that they do; it’s quite another to accept personal responsibility for providing this education to patients face-to-face.

No patient should ever be allowed to walk out of a doctor’s office, hospital, clinic, or pharmacy without face-to-face instructions on the use of fentaNYL patches and related safety concerns, as well as verification of consumer understanding. Everyone must take responsibility and never assume someone else will act. The change necessary to improve patient safety will always depend on individuals who, never satisfied with being a bystander, are drawn into the lifesaving work of keeping patients safe from harm. Widespread adoption of required consumer education will also be more effective if influential groups work together and if external forces provide the necessary pressure via regulations, standards, public policy, or incentives.

This column was prepared by the Institute for Safe Medication Practices (ISMP), an independent, nonprofit charitable organization dedicated entirely to medication error prevention and safe medication use. Any reports described in this column were received through the ISMP Medication Errors Reporting Program. Errors, close calls, or hazardous conditions may be reported online at www.ismp.org or by calling 800-FAIL-SAFE (800-324-5723). ISMP is a federally certified patient safety organization (PSO), providing legal protection and confidentiality for patient safety data and error reports it receives. Visit www.ismp.org for more information on ISMP’s medication safety newsletters and other risk reduction tools. This article appeared originally in the August 8, 2013, issue of the ISMP Medication Safety Alert!

Carson, H. J., Knight, L. D., Dudley, M. H., et al. (2010). A fatality involving an unusual route of fentanyl delivery: chewing and aspirating the transdermal patch. Legal Medicine, 12, 157-159.
Faust, A. C., Terpolilli, R., Hughes, D. W. (2011). Management of oral ingestion of transdermal fentanyl patches: A case report and literature review. Case Reports in Medicine, article ID 495938, 4 pages.
Geller, E. S. (2001). The psychology of safety handbook. Boca Raton, FL: CRC Press LLC.
ISMP. (2005, August 11). New fentaNYL warnings: more needed to protect patients. ISMP Medication Safety Alert! 10(16), 1-3.
ISMP. (2012). A top-10 list. Protecting young children from medicine mishaps. Safe Medicine, 10(6), 1-3.
Mrvos, R., Feuchter, A. C., Katz, K. D., et al. (2012). Whole fentanyl patch ingestion: A multi-center case series. Journal of Emergency Medicine, 42(5), 549-552.
National Alert Network (NAN). (2012, April 25). Proper disposal of fentaNYL patches is critical to prevent accidental exposure. Available at http://www.ismp.org/NAN/files/NAN-20120425.pdf.
Neary, B. (2013, July 25). Relatives of Montana man sue hospital over death. Associated Press. Lexington Herald-Leader.
Teske, J., Weller Jens-Peter, Larsh, K., et al. (2007). Fatal outcome in a child after ingestion of a transdermal fentanyl patch. International Journal of Legal Medicine, 121, 147-51.
U.S. Food and Drug Administration (FDA). (2012, April 18). FDA reminds the public about the potential for life-threatening harm from accidental exposure to fentanyl transdermal systems (“patches”). Available at http://www.fda.gov/Drugs/DrugSafety/ucm300747.htm.